

SENATE SUMMARY OF HOUSE AMENDMENTS

SB 283

2018 Regular Session

Mills

KEYWORD AND SUMMARY AS RETURNED TO THE SENATE

HEALTH/ACC INSURANCE. Provides relative to pharmacy benefit managers. (8/1/18)

SUMMARY OF HOUSE AMENDMENTS TO THE SENATE BILL

1. Change the time period for reporting price increases from not less than 30 days prior to the increase to not more than 30 days after the increase.
2. Change the due date of the first transparency report from Feb. 1, 2019, to June 1, 2020.
3. Change the deadline for DOI to publish a transparency report from 10 to 60 days after receipt.
4. Removes provisions that regarding enforcement by the commissioner of insurance and for suspension or revocation of a pharmacy benefit manager's license for failure to comply with proposed law.
5. Adds provisions requiring a pharmaceutical drug manufacturer to notify the commissioner of insurance by electronic mail of any drug price increase of 50% or greater not more than 30 days after the price increase.

DIGEST OF THE SENATE BILL AS RETURNED TO THE SENATE

SB 283 Reengrossed

2018 Regular Session

Mills

Present law requires pharmacy benefit managers to be licensed by the Dept. of Insurance (DOI).

Proposed law retains present law and further requires DOI to have a dedicated location on the department's website to publish pharmacy benefit manager information, including the formulary and timely notification of formulary changes by each licensed pharmacy benefit manager.

Proposed law requires pharmacy benefit managers beginning June 1, 2020, to issue an annual transparency report that discloses aggregate data on rebates received from drug manufacturers, administrative fees, and aggregate rebates received that did not pass through to the health benefit plan or insurer. Further requires DOI to publish the transparency report within 60 days of receipt from the pharmacy benefit manager.

Proposed law requires that not more than 30 days after an increase in wholesale acquisition cost of 50% or greater for a drug with a wholesale acquisition cost of \$100 or more for a 30 supply, a pharmaceutical drug manufacturer is to notify the commissioner of insurance by electronic mail of the change.

Proposed law provides for an exception to the Public Records Law.

Effective August 1, 2018.

(Amends R.S. 22:1657 and R.S. 44:4.1(B)(11); adds R.S. 22:1657.1)

Thomas L. Tyler
Deputy Chief of Staff